Cargrilintide

Elevate Your Metabolic Health with Cagrilintide

Cagrilintide is a synthetic, long-acting amylin analog designed as a dual agonist of amylin receptors (AMYR) and calcitonin receptors (CTR). This peptide mimics the physiological effects of amylin, a hormone co-secreted with insulin by pancreatic beta cells, and is known for its potential in treating obesity, type 2 diabetes, and related metabolic disorders.

Key Benefits and Research Applications of Cagrilinitide:

Dual Receptor Agonism: Cagrilintide acts as a non-selective agonist of amylin and calcitonin receptors, promoting satiety, reducing food intake, and stabilizing blood glucose levels by slowing gastric emptying and suppressing glucagon secretion postprandially.

Weight Loss Efficacy: Clinical trials have demonstrated significant weight loss, with studies showing up to 10.8% body weight reduction over 26 weeks at a 4.5 mg dose, outperforming liraglutide (9.0%) and placebo (3.0%). When combined with Tirzepatide, weight loss reached 20.4% over 68 weeks in phase 3 trials.

Metabolic Health Benefits: Enhances glycemic control by reducing HbA1c levels and improving insulin sensitivity, making it a promising candidate for managing type 2 diabetes and obesity-related comorbidities.

Combination Therapy Potential: Shows synergistic effects when co-administered with GLP-1 receptor agonists like Tirzepatide, leading to greater weight loss and improved metabolic outcomes compared to either peptide alone.

Step into the future of weight management science with Cagrilintide – a powerful, long-acting amylin analogue engineered for appetite control and obesity. With proven synergy alongside GLP-1 agonists, Cagrilintide offers unmatched potential in metabolic pathway exploration.